Krsnaa Diagnostics Announces Highest-Ever Quarterly Profit in Q2 FY26
Krsnaa Diagnostics reports record quarterly profit with revenue at ₹2,060 million, EBITDA at ₹602 million, and PAT at ₹239 million. The company received ACR accreditation and was recognized as India's Most Trusted Diagnostic Brand.
The company's highest-ever quarterly profit, coupled with international recognition and expansion plans, suggests a significant positive impact on its growth trajectory and market position.
The announcement highlights strong financial performance with significant YoY growth in revenue, EBITDA, and PAT. The company also received international accreditations, indicating enhanced credibility and service quality.
* Krsnaa Diagnostics Ltd. announced its Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025. * Revenue for Q2 FY26 stood at ₹2,060 million, an 11% YoY increase. * EBITDA for Q2 FY26 was ₹602 million, up by 18% YoY. * PAT for Q2 FY26 reached ₹239 million, a 22% YoY increase. * EPS for Q2 FY26 was ₹7.25, a 23% YoY increase. * The company's H1 FY26 revenue grew by 12% year-on-year, driven by expanding patient volumes. * EBITDA increased 18% year-on-year to ₹1,126 million, with margins improving to 28%. * Net profit rose 19% to ₹445 million. * The Rajasthan PPP project is progressing well, with meaningful revenue contribution expected from Q4 FY26 and a full-year impact in FY27. * Krsnaa Diagnostics received accreditation from the American College of Radiology (ACR), the first-ever ACR recognition outside the United States. * The company was honored as “India’s Most Trusted Integrated Diagnostic Brand” at the Big FM – Big Impact Awards in Vietnam. * Management Commentary: Mr. Yash Mutha, Managing Director, stated that Krsnaa Diagnostics has delivered its highest-ever quarterly profit, reinforcing the strength and resilience of their business model.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.